DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Arnd - 2 Ludwig Burger - 2 Rachel More - 2 drugmaker Roche - 1 ROG.S - 1 Eli Lilly - 1 Swiss drugmaker - 1 Roche - 1
Top related locs:
Basel Switzerland Swiss . Alzheimer's Lonza Zurich Frankfurt
Top related orgs:
REUTERS - 2 Thomson - 2 Rights - 1 Carmot Therapeutics - 1 Novo Nordisk - 1 AstraZeneca - 1 Pfizer - 1 Monday - 1

Search resuls for: "Ludwig Burger Noele Illien"


2 mentions found


☆ Roche enters obesity drug market with $2.7 bln Carmot deal
  + stars: | 2023-12-04 | by ( Ludwig Burger Noele Illien | Ludwig Burger | Noele Illien | ) www.reuters.com   time to read: +2 min
The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland January 30, 2020. REUTERS/Arnd Wiegmann/File Photo Acquire Licensing RightsZURICH, Dec 4 (Reuters) - Roche (ROG.S) agreed to take over obesity drug developer Carmot Therapeutics (CRMO.O) for $2.7 billion, joining a list global contestants seeking to challenge the dominant makers of weight-loss drugs Novo Nordisk (NOVOb.CO) and Eli Lilly. After encouraging Phase I trial results, the drug is ready to be tested on humans in the second of three trial stages, Roche added. Among recent deals to acquire obesity drug development projects, AstraZeneca (AZN.L) last month agreed to pay up to $2 billion for the rights to an experimental pill from China's Eccogene. Roche will obtain access to Carmot's current R&D portfolio including all clinical and preclinical assets.
Persons: drugmaker Roche, Arnd, ROG.S, Eli Lilly, Swiss drugmaker, Roche, . New Roche, Thomas Schinecker, Ludwig Burger, Noel Illien, Rachel More, Louise Heavens Organizations: REUTERS, Rights, Carmot Therapeutics, Novo Nordisk, AstraZeneca, Pfizer, Thomson Locations: Basel, Switzerland, Swiss, ., Alzheimer's
☆ Lonza CEO departure prompts concern over earnings prospects
  + stars: | 2023-09-18 | by ( Ludwig Burger Noele Illien | Ludwig Burger | Noele Illien | ) www.reuters.com   time to read: +2 min
The logo of Swiss contract drug maker Lonza is seen at its headquarters in Basel, Switzerland October 1, 2020. Shares in Lonza, which makes drug ingredients for healthcare and biotech companies, dropped 5.3% shortly after the 0700 GMT market open, trading near an eight-month low. A former Roche executive who joined Lonza in 2020, Ruffieux oversaw the company's role in producing COVID-19 vaccines for Moderna (MRNA.O) during the pandemic. "Today’s announcement increases our conviction that the new mid-term targets will not include an acceleration in growth," they said. Lonza did not provide a reason for Ruffieux's departure.
Persons: Arnd, Pierre, Alain Ruffieux, Lonza, Albert Baehny, Ruffieux, Morgan, Spokespeople, Merck KGaA, Noele, Ludwig Burger, Rachel More, David Goodman, Emelia Organizations: REUTERS, Monday, Ruffieux, Roche, Lonza, Moderna, Merck, Noele Illien, Thomson Locations: Basel, Switzerland, Swiss, Lonza, Zurich, Frankfurt
0 next >>
Total: 2